Company

Charles (Chuck) Bramlage
President and CEO

Kevin Ferro
CEO and CIO, Vatera Holdings LLC

James W. Young, PhD
Venture Partner, 5AM Ventures

James Niedel, MD, PhD
Managing Director, New Leaf Ventures

Howard B. Rosen
Independent Member

Nicholas Simon
Managing Director, Clarus Ventures

Sundar Kodiyalam
Managing Director, Vatera Holdings LLC

Thomas Paul Koestler, PhD
Executive Director, Vatera Holdings LLC

Steven Jaharis, M.D.
Family Practitioner, Winnetka Family Medicine

Charles (Chuck) Bramlage

President and CEO

Mr. Bramlage is currently chief executive officer of Pearl Therapeutics. He previously was president of pharmaceutical products at Covidien plc. Earlier, Mr. Bramlage served as president of European operations at Valeant Pharmaceuticals International and president and chief executive officer of BattellePharma, Inc., a specialty pharmaceutical company developing inhaled products. In addition, he was formerly the vice president of respiratory global commercial development and vice president of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline, where he led the team responsible for the global launch of Seretide®/Advair® and the U.S. launch of Flovent®. His earlier career involved various positions at GSK and Merck in product management, sales management, sales, and sales training. He and his teams have launched over 40 brands in 14 therapeutic areas.

Mr. Bramlage holds an MBA from the University of Dayton and a BS Administrative Science in Marketing from The Ohio State University.

Go to Top

Kevin Ferro

CEO and CIO, Vatera Holdings LLC

Kevin Ferro is Chief Executive Officer and Chief Investment Officer of Vatera Holdings LLC. Mr. Ferro is the chairman of the Boards of Directors of Arisaph Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on developing novel therapies for cancer, cardiovascular disease and diabetes, and ImmusanT Inc., a biotechnology company focused on developing a treatment and a set of diagnostic and monitoring tools to manage patients with celiac disease, and a member of the boards of Rib-X Pharmaceuticals, Inc., a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections, and Ekteino Laboratories, Inc., an early-stage biopharmaceutical company focused on utilizing its proprietary biopolymer technology to achieve controlled and sustained delivery of drugs. Mr. Ferro was previously a member of the board of directors of Kos Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of chronic diseases with a focus on cardiovascular, metabolic and respiratory diseases.

Mr. Ferro also serves as the Chief Executive Officer and Chief Investment Officer of Ferro Capital LLC, an investment advisory firm. Prior to forming Ferro Capital in 2001, Mr. Ferro was the Global Head of Alternative Investment Strategies for Commerzbank, one of Germany’s largest listed banks. Prior to Commerzbank, Mr. Ferro was a Vice President at D. E. Shaw & Co. LP. Mr. Ferro has an AB in Government from Harvard University.

Go to Top

James W. Young, PhD

Venture Partner, 5AM Ventures

James W. Young has over 20 years of experience in the biopharmaceutical industry. He has been a Venture Partner at 5AM Ventures since 2006. He is Chairman of the Board at Sunesis Pharmaceuticals, where he earlier was Chief Executive Officer and more recently Executive Chairman. Prior to Sunesis, he served as Senior Vice President, Research and Development, and as Group Vice President at ALZA Corporation. Before joining ALZA, Dr. Young was President of the Pharmaceuticals Division of Affymax, N.V., and Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Corp. Earlier, Dr. Young was Vice President for Research at Zoecon Corporation/Sandoz Crop Protection Corporation. He earned a BS in Chemistry from Fordham University and a PhD in Organic Chemistry from Cornell University.

Go to Top

James Niedel, MD, PhD

Managing Director, New Leaf Ventures

Dr. James Niedel is one of the founders of New Leaf Ventures, specializing in biopharmaceutical and diagnostic investments. He was a venture partner with the Sprout Group since 2002, one of the early venture capital groups with a life science focus. Prior to joining the venture industry, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995, he was VP Research and SVP R&D for the US subsidiary of Glaxo. Before joining the pharmaceutical industry, Dr. Niedel was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received MD and PhD (Biochemistry) degrees from the University of Miami, was selected a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).

Go to Top

Howard B. Rosen

Independent Member

Howard B. Rosen is currently a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies, most recently as President of the ALZA division of Johnson & Johnson. During his tenure at ALZA, he was responsible for product development activities, portfolio management, corporate and new product planning, mergers and acquisitions, R&D planning and technology ventures.

Prior to ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., served as Director of Corporate Development at GenPharm International, Inc., and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen also serves on the Boards of Directors of AcelRx Pharmaceuticals, Inc., PaxVax, Inc. and CNS Therapeutics, Inc.

Mr. Rosen holds an M.B.A. from the Stanford Graduate School of Business, an M.S. in chemical engineering from the Massachusetts Institute of Technology, and a B.S. in chemical engineering from Stanford University. He is a member of the National Academy of Engineering.

Go to Top

Nicholas Simon

Managing Director, Clarus Ventures

Nicholas Simon is a Managing Director at Clarus Ventures, LLC, a venture capital company he co-founded in February, 2005, which is focused on investing in life sciences companies. Since October 2001, Mr. Simon has been a General Partner at MPM BioVentures III. From April 2000 to July 2001, Mr. Simon was Chief Executive Officer, Founder, and Director of Collabra Pharma, Inc., a pharmaceutical development company. From 1989 to 2000, Mr. Simon served in various management positions at Genentech, Inc., a biotechnology company, including Vice President of Business and Corporate Development. Mr. Simon represents Clarus on the Board of Directors of Achillion Pharmaceuticals, Inc. (ACHN), ARYx Therapeutics (ARYX), Avanir Pharmaceuticals (AVNR), Pearl Therapeutics Inc., and Sientra Inc. In addition he is also a member of the board of directors for Poniard, Inc. (PARD) and QuatRx Pharmaceuticals. Previous directorships include Barrier (acquired by Stiefel Laboratories, Inc.) CoTherix (NASDAQ:CTRX), Neosil, and Rigel (NASDAQ:RIGL).

He is also on the Advisory Council at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California San Francisco (UCSF). Mr. Simon received a B.S. in Microbiology from the University of Maryland and an M.B.A. in Marketing from Loyola College.

Go to Top

Sundar Kodiyalam

Managing Director, Vatera Holdings LLC

Sundar Kodiyalam is a Managing Director of Vatera Holdings LLC. Prior to Vatera, Mr. Kodiyalam worked as Senior VP, Commercial Development & New Business Ventures at Kos Pharmaceuticals. During his four year tenure at Kos, sales contributions from licensed products grew from 0% to more than 25% as a result of transactions completed by Mr. Kodiyalam and his team. The company also boasted a robust late-stage pipeline partially built through successful licensing efforts. Mr. Kodiyalam was also a key member of the management team that worked on the sale of Kos Pharmaceuticals to Abbott Labs. Prior to Kos, Mr. Kodiyalam was VP of Commercial Development at Ortec International, a tissue engineering company. Mr. Kodiyalam's experience with Big Pharma includes three years at Schering Plough as Director of Business Development & Licensing and ten years at Novartis Pharmaceuticals in domestic and international marketing roles. Mr. Kodiyalam currently also serves on the BOD of Ascio Pharmaceuticals and Ekteino Laboratories. Mr. Kodiyalam has a M.S. in Pharmaceutical Administration from Ohio State University and B. Pharmacy from Madras University, India.

Go to Top

Thomas Paul Koestler, PhD

Executive Director, Vatera Holdings LLC

Dr. Koestler is an Executive Director of Vatera Holdings LLC who has been working with the firm since 2010. In his nearly 30-year career in the pharmaceutical industry, Dr. Koestler established a track record of building high-performance teams that drove global success in Research and Development. Most recently he served as Executive Vice President of Schering Corporation and President of Schering-Plough Research Institute (SPRI), the pharmaceutical Research and Development arm of Schering-Plough Corporation. Under his leadership, the company developed an industry-leading pipeline that contributed to the turnaround of the business. Dr. Koestler’s accomplishments include over 80 product approvals including over 30 New Molecular Entities/BLAs.

Before joining Schering-Plough, he was Senior Vice President and Head of Global Regulatory Affairs for Pharmacia Corporation. Prior to joining Pharmacia, Dr. Koestler was Senior Vice President and Global Head, Drug Regulatory Affairs, Compliance Assurance, Clinical Safety and Epidemiology for Novartis. Before that appointment, he was Senior Director, Drug Regulatory Affairs, at Ortho McNeil and a Director of Regulatory Affairs at Bristol-Myers Squibb, Westwood Pharmaceuticals.

Dr. Koestler is a member of the Board of Directors of Novo Nordisk A/S, Momenta Pharmaceuticals Inc., ImmusanT Inc, Arisaph Pharmaceuticals Inc, and Rib-X Pharmaceuticals. Dr. Koestler also chairs the Scientific Advisory Board of Bausch & Lomb.

Dr. Koestler has a Bachelor of Science, Biology, from Daemen College from 1975 and a PhD in Medicine & Pathology from the Roswell Park Memorial Institute from 1982.

Go to Top

Steven Jaharis, M.D.

Family Practitioner, Winnetka Family Medicine

Dr. Jaharis has been a practicing physician since 1990 and currently serves as a family practitioner at Winnetka Family Medicine. He serves on the Board of Overseers of Tufts University School of Medicine, Board of Managers of Haverford College and also served as a Director of Kos Pharmaceuticals, Inc., prior to its acquisition by Abbott Laboratories in 2006. Dr. Jaharis received his undergraduate degree from Haverford College, his medical degree from Tufts University School of Medicine, and completed his residency at Cook County Hospital in Chicago. Dr. Jaharis currently serves as a Director of Arisaph Pharmaceuticals, Inc. Dr. Jaharis also serves as a Director of the Jaharis Family Foundation.

Go to Top